
    
      The duration of screening, treatment, and follow-up are within 21 days, 3 weeks/cycle, and 90
      days after the last aflibercept administration. Patients will be administered aflibercept in
      combination with docetaxel until when/if a definitive treatment discontinuation criterion is
      met such as progressive disease, unacceptable toxicity or patient refusal to continue.
    
  